In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year history Excluding milestone ...

Samsung Bioepis, a subsidiary of Samsung Epis Holdings, achieved its highest annual sales performance last year. According to ...

Dr Reddy's Laboratories Ltd (RDY) reports steady revenue growth driven by emerging markets and strategic collaborations, ...

This past year contained a number of significant developments in litigation involving biologics and biosimilars. The following is a recap of the ...

Amgen Inc. Buy thesis: strong pipeline, 12% Q3 2025 revenue growth and MariTide obesity upside. Click for this updated look ...

Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. See why ALVO stock is a Strong Buy.

Objective China has a high disease burden of low bone mass, and elderly men with excessive alcohol consumption may be underdiagnosed and undertreated given the adverse effects on skeletal health. This ...

India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved a wide range of recombinant DNA (r-DNA)-origin drugs and biologics for manufacture ...

The US biosimilar market evolves with 90 approvals, significant price drops, and new PBM models enhancing access to ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...